The effect of systemic corticosteroid therapy on the expression of toll-like receptor 2 and toll-like receptor 4 in the cutaneous lesions of leprosy Type 1 reactions

British Journal of Dermatology

Volumn 167, Issue 1, 2012, Pages 29-35

  Walker, Stephen L ^a   Roberts, C H ^a   Atkinson, S E ^a   Khadge, S ^b   Macdonald, M ^b   Neupane, K D ^b   Ranjit, C ^b   Sapkota, B R ^b   Dhakal, S ^b   Hawksworth, R A ^b   Mahat, K ^b   Ruchal, S ^b   Hamal, S ^b   Hagge, D A ^b   Lockwood, D N J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Anandaban Leprosy Hospital   (Nepal)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; DAPSONE; METHYLPREDNISOLONE; PREDNISOLONE; RIFAMPICIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ADULT; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFECT; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LEPROSY; LEPROSY TYPE 1 REACTION; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SKIN BIOPSY; TREATMENT DURATION;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIBIOTICS, ANTITUBERCULAR; DNA, COMPLEMENTARY; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION; GLUCOCORTICOIDS; HUMANS; IMMUNOHISTOCHEMISTRY; LEPROSY; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PREDNISOLONE; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; YOUNG ADULT;

EID: 84863332908     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10891.x     Document Type: Article

References (20)

1. Lockwood DNJ. Leprosy. In: Rook's Textbook of Dermatology (Burns DA, Breathnach SM, Cox NH, Griffiths CEM, eds), 7th edn, Vol. 2. Oxford: Blackwell Publishing, 2004; 29.1-29.21.
2. Rao PS, Sugamaran DS, Richard J et al. Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy. Lepr Rev 2006; 77:25-33.
3. Walker SL, Lockwood DN. Leprosy type 1 (reversal) reactions and their management. Lepr Rev 2008; 79:372-86.
4. Krutzik SR, Ochoa MT, Sieling PA et al. Activation and regulation of toll-like receptors 2 and 1 in human leprosy. Nat Med 2003; 9:525-32. (Pubitemid 36597097)
5. Bochud PY, Hawn TR, Siddiqui MR et al. Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. J Infect Dis 2008; 197:253-61. (Pubitemid 351263444)
6. Bochud PY, Sinsimer D, Aderem A et al. Polymorphisms in toll-like receptor 4 (TLR4) are associated with protection against leprosy. Eur J Clin Microbiol Infect Dis 2009; 28:1055-65.
7. Misch EA, Macdonald M, Ranjit C et al. Human TLR1 deficiency is associated with impaired mycobacterial signaling and protection from leprosy reversal reaction. PLoS Negl Trop Dis 2008; 2:e231.
8. Johnson CM, Lyle EA, Omueti KO et al. Cutting edge: a common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol 2007; 178:7520-4. (Pubitemid 46898019)
9. Job CK. Pathology of leprosy. In: Leprosy (Hastings RC, ed.), 2nd edn. Edinburgh: Churchill Livingstone, 1994; 193-234.
10. Walker SL, Nicholls PG, Dhakal S et al. A phase two randomised controlled double blind trial of high dose intravenous methylprednisolone and oral prednisolone versus intravenous normal saline and oral prednisolone in individuals with leprosy type 1 reactions and/or nerve function impairment. PLoS Negl Trop Dis 2011; 5:e1041.
11. Moher D, Schulz KF, Altman DG. The consort statement: revised recommendations for improving the quality of reports of parallelgroup randomised trials. Lancet 2001; 357:1191-4. (Pubitemid 32378696)
12. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25:402-8. (Pubitemid 34164012)
13. Renn CN, Sanchez DJ, Ochoa MT et al. TLR activation of langerhans cell-like dendritic cells triggers an antiviral immune response. J Immunol 2006; 177:298-305. (Pubitemid 43939141)
14. Little D, Khanolkar-Young S, Coulthart A et al. Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. Infect Immun 2001; 69:3413-17. (Pubitemid 32332240)
15. Lockwood DN, Colston MJ, Khanolkar-Young SR. The detection of Mycobacterium leprae protein and carbohydrate antigens in skin and nerve from leprosy patients with type 1 (reversal) reactions. Am J Trop Med Hyg 2002; 66:409-15. (Pubitemid 34810496)
16. Khanolkar-Young S, Rayment N, Brickell PM et al. Tumour necrosis factor-alpha (TNF-alpha) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin Exp Immunol 1995; 99:196-202.
17. Gay NJ, Gangloff M. Structure and function of toll receptors and their ligands. Annu Rev Biochem 2007; 76:141-65.
18. Doz E, Rose S, Nigou J et al. Acylation determines the toll-like receptor (TLR)-dependent positive versus TLR2-, mannose receptor-, and SIGNR1-independent negative regulation of pro-inflammatory cytokines by mycobacterial lipomannan. J Biol Chem 2007; 282:26014-25. (Pubitemid 47443801)
19. Galon J, Franchimont D, Hiroi N et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J 2002; 16:61-71. (Pubitemid 34027951)
20. Rozkova D, Horvath R, Bartunkova J et al. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of toll-like receptors. Clin Immunol 2006; 120:260-71. (Pubitemid 44175897)